Allegra-d 24 Hour Allergy And Congestion is a drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is protected by 10 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 25, 2020. Details of Allegra-d 24 Hour Allergy And Congestion's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6613357 | Osmotic device containing pseudoephedrine and an H1 antagonist |
Dec, 2020
(4 years ago) |
Expired
|
| USRE39069 | Multi-layered osmotic device |
May, 2018
(7 years ago) |
Expired
|
|
US6037353 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Sep, 2017
(8 years ago) |
Expired
|
| US6037353 | Method of providing an antihistaminic effect in a hepatically impaired patient |
Mar, 2017
(8 years ago) |
Expired
|
|
US7138524 (Pediatric) | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(10 years ago) |
Expired
|
|
US5578610 (Pediatric) | Piperidine derivatives |
May, 2014
(11 years ago) |
Expired
|
| US7138524 | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(11 years ago) |
Expired
|
| US5578610 | Piperidine derivatives |
Nov, 2013
(11 years ago) |
Expired
|
|
US6187791 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(12 years ago) |
Expired
|
|
US6399632 (Pediatric) | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(12 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Allegra-d 24 Hour Allergy And Congestion's patents.
Latest Legal Activities on Allegra-d 24 Hour Allergy And Congestion's Patents
Given below is the list of recent legal activities going on the following patents of Allegra-d 24 Hour Allergy And Congestion.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent
Critical | 19 Dec, 2014 | US7138524 |
| Recordation of Patent Grant Mailed
Critical | 21 Nov, 2006 | US7138524 |
| Patent Issue Date Used in PTA Calculation
Critical | 21 Nov, 2006 | US7138524 |
| Issue Notification Mailed
Critical | 01 Nov, 2006 | US7138524 |
| Dispatch to FDC | 20 Oct, 2006 | US7138524 |
| Application Is Considered Ready for Issue
Critical | 03 Oct, 2006 | US7138524 |
| Mail Response to 312 Amendment (PTO-271)
Critical | 02 Oct, 2006 | US7138524 |
| Response to Amendment under Rule 312
Critical | 29 Sep, 2006 | US7138524 |
| Issue Fee Payment Verified
Critical | 06 Sep, 2006 | US7138524 |
| Information Disclosure Statement (IDS) Filed
Critical | 06 Sep, 2006 | US7138524 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets
invalidated somehow, the
generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal
pitfalls. Given
below are details of the litigation history of Allegra-d 24 Hour Allergy And Congestion and ongoing
litigations to
help you estimate the early arrival of Allegra-d 24 Hour Allergy And Congestion generic.
Allegra-d 24 Hour Allergy And Congestion's Litigations
Allegra-d 24 Hour Allergy And Congestion been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 02, 1999, against patent number US6037353. The petitioner , challenged the validity of this patent, with YOUNG as the respondent. Click below to track the latest information on how companies are challenging Allegra-d 24 Hour Allergy And Congestion's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6037353 | November, 1999 |
Decision
(02 Nov, 1999) | YOUNG | |
US patents provide insights into the exclusivity only within the United States, but
Allegra-d 24 Hour Allergy And Congestion is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Allegra-d 24 Hour Allergy And Congestion's family patents as well as insights into
ongoing legal events
on those patents.
Allegra-d 24 Hour Allergy And Congestion's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Allegra-d 24 Hour Allergy And Congestion's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 25, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Allegra-d 24 Hour Allergy And Congestion Generic API suppliers:
Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride is the generic name for the brand Allegra-d 24 Hour Allergy And Congestion. 8 different companies have already filed for the generic of Allegra-d 24 Hour Allergy And Congestion, with Dr Reddys having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Allegra-d 24 Hour Allergy And Congestion's generic
How can I launch a generic of Allegra-d 24 Hour Allergy And Congestion before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Allegra-d 24 Hour Allergy And Congestion's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Allegra-d 24 Hour Allergy And Congestion's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Allegra-d 24 Hour Allergy And Congestion -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 180 mg/240 mg | 06 Jun, 2007 | 1 | 22 Jun, 2011 | 25 Dec, 2020 | Eligible |
Alternative Brands for Allegra-d 24 Hour Allergy And Congestion
Allegra-d 24 Hour Allergy And Congestion which is used for treating symptoms of respiratory allergies, nasal swelling, sinus congestion, and pressure in adults and children 12 years and older., has several other brand drugs in the same treatment category and using the same active ingredient (Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Chattem Sanofi |
| |||
Apart from brand drugs containing the same ingredient, some generics have also been filed for Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride, Allegra-d 24 Hour Allergy And Congestion's active ingredient. Check the complete list of approved generic manufacturers for Allegra-d 24 Hour Allergy And Congestion
About Allegra-d 24 Hour Allergy And Congestion
Allegra-D 24 Hour Allergy And Congestion is a drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is used for treating symptoms of respiratory allergies, nasal swelling, sinus congestion, and pressure in adults and children 12 years and older. Allegra-D 24 Hour Allergy And Congestion uses Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride as an active ingredient. Allegra-D 24 Hour Allergy And Congestion was launched by Chattem Sanofi in 2011.
Approval Date:
Allegra-d 24 Hour Allergy And Congestion was approved by FDA for market use on 24 January, 2011.
Active Ingredient:
Allegra-d 24 Hour Allergy And Congestion uses Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Fexofenadine Hydrochloride; Pseudoephedrine Hydrochloride ingredient
Treatment:
Allegra-d 24 Hour Allergy And Congestion is used for treating symptoms of respiratory allergies, nasal swelling, sinus congestion, and pressure in adults and children 12 years and older.
Dosage:
Allegra-d 24 Hour Allergy And Congestion is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 180MG;240MG | TABLET, EXTENDED RELEASE | Over the counter | ORAL |